TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) announces the multicenter publication of independent research which reports an association between calcifying nanoparticles (CNPs) and aortic stenosis. Aortic stenosis represents the most frequent cause of heart valve replacement (Bratos-Pérez et al, European Heart Journal Advance Access, doi:10.1093/eurheartj/ehm592).
